Basel, Switzerland
Cellestia Biotech is a Swiss-based biopharma startup founded in 2014. The company's mission is to develop targeted therapies for cancer patients with no other options, with a focus on orphan cancers and childhood leukemia. Their flagship drug candidate, CB-103, has shown promising results in terms of safety and biological activity in humans. Cellestia is currently carrying out Phase 2 Investigator-Initiated Trials (IITs) for multi-drug resistant cancers and is planning a Proof-of-Concept clinical study for graft-versus-host disease (GvHD).
Recently, the company received a non-equity assistance investment on 27 June 2023 from Swissnex San Francisco. With a focus on innovative therapeutics for autoimmune diseases and multi-drug resistant cancers, Cellestia Biotech is positioned as a promising player in the biopharma and biotechnology sectors, as well as the broader health care and wellness industries.
